Insmed

Valuation Analysis

About the Company

Insmed en bref

Insmed (INSM) is currently trading at 83,60 € with a market capitalization of 18,1 Md €. The 52-week range spans from 78,88 € to 185,66 €; the current price is 55% below the yearly high. Year-over-year revenue growth stands at +229.6%.

💰 Dividende

Insmed currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

21 analystes évaluent Insmed (INSM) au consensus : Achat Fort. L'objectif de cours moyen est de 172,04 €, soit un potentiel de +105.79% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 122,17 € à 212,06 €.

Insmed : la thèse d'investissement en détail

Insmed (INSM) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 229.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 81.81%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 105.79% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

The PEG ratio at 1.09 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

Signal Smart Money

On the institutional side, Insmed appears in the disclosed holdings of Druckenmiller. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 105.79% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (9.95%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Insmed?

Compare top-rated brokers — low fees, trusted providers, fully regulated.